Insight velocity
Turn days of work into hours with reliable AI-driven analysis.


















































Purpose-built for teams who need real insights—so you can focus on decisions, not research.

Purpose-built for teams who need real insights—so you can focus on decisions, not research.
Strategic decisions deserve more than gut checks and stale decks. Maven Bio gives your team evidence-backed insights—and a living view of the market that doesn't go stale the moment it's built.







Speed is table stakes. Maven Bio gives your team the primary-source depth to deliver work that wins engagements—and keeps them.





IC questions deserve real answers. Maven Bio surfaces primary source analysis so your team builds theses that hold up under pressure.







Turn days of work into hours with reliable AI-driven analysis.
Execute large-scale screens once too slow or impractical to run.
Operationalize your frameworks so they're applied consistently by everyone.
Every insight tied directly to primary sources and reasoning for defensible decisions.

Powered by the most expansive collection of curated life sciences data.

Powered by the most expansive collection of curated life sciences data.






In 2025, the FDA approved 46 new drugs across oncology, immunology, neurology, and rare diseases. This report examines key approval trends, mechanisms, and therapeutic focus areas shaping biopharma strategy.

An analysis of the largest pharma and biotech M&A deals of 2025, examining how Big Pharma deployed capital toward late-stage assets, platform technologies, and durable therapeutic franchises amid rising development costs and approaching patent expiries.

A structured review of U.S. pharma manufacturing and R&D site investments announced in 2025, highlighting where capital was deployed, which companies announced site level expansions or new builds, and how these moves reinforce long term U.S. supply strategies.